Dr. Jacqueline Lui, Managing Director of Eagle IP Limited, and Dr. H.C. Lui, Director of Eagle IP Limited, participated the Israel-Asia Summit 2013 in Israel, with the S.T.A.R.S. Foundation delegation.

Our Past Events

Recommended Insights

Major and Exciting Changes to China’s Patent Law [Fourth Amendment to China's Patent Law]

20 February 2019
Major changes are on the horizon for China’s Patent Law, which will see an overhaul in many areas as early as this year (2019). On January 4, 2019, the National People’s Congress in China published the latest draft of the Fourth Amendment to China’s Patent Law. Several draft amendments have been released for public comment […]

New Fee Standards Released for Chinese Patent Applications

6 September 2024
Recently, the Chinese government issued four official notices introducing new fee standards and deduction rules for Chinese patent applications.1 These updates address international applications (PCT applications) and the Chinese national phase applications thereof, as well as patent term adjustment/extension (PTA/PTE). Please find our summary below: PCT application fee deduction rules   Application fee & extra […]

How the Chinese Patent Office Rejected a Plate-Making Method Based on Food Safety Law

19 October 2022
Previously we published an article about CNIPA rejecting a patent application claiming a food that could also be used to treat or prevent diseases based on the food’s alleged non-compliance with Food Safety Law. China’s Food Safety Law includes a provision which states any use of a composition as a food must be strictly separated […]

Can I transfer priority rights in China without the consent of other applicants? Insights from the Broad Institute’s CRISPR patent

4 February 2025
The high-profile disputes surrounding an important CRISPR patent belonging to The Broad Institute, MIT and Harvard (hereinafter “the proprietors”) has attracted a lot of attention in recent years, particularly regarding the validity of priority rights that were challenged worldwide. In Europe, the patent was famously revoked by the European Patent Office (hereinafter “EPO”) due to […]
Top crossarrow-right